サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：定量噴霧式吸入器の世界市場（製品タイプ：手動式pMDIと呼吸式pMDI；疾患適応：喘息、COPD、その他）-産業分析、サイズ、シェア、成長、動向、および予測、2022-2031年
市場調査レポート
商品コード
1229577

定量噴霧式吸入器の世界市場（製品タイプ：手動式pMDIと呼吸式pMDI；疾患適応：喘息、COPD、その他）-産業分析、サイズ、シェア、成長、動向、および予測、2022-2031年

Metered Dose Inhalers Market (Product Type: Manual Actuated pMDIs and Breath Actuated pMDIs; Disease Indication: Asthma, COPD, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 216 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
定量噴霧式吸入器の世界市場（製品タイプ：手動式pMDIと呼吸式pMDI；疾患適応：喘息、COPD、その他）-産業分析、サイズ、シェア、成長、動向、および予測、2022-2031年
出版日: 2023年01月18日
発行: Transparency Market Research
ページ情報: 英文 216 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

本レポートでは、2022年を基準年、2031年を予測年として考慮し、2017年から2031年にかけての世界の定量噴霧式吸入器市場の収益を掲載しています。また、2022年から2031年までの世界の定量吸入器市場の複合年間成長率（CAGR %）を掲載しています。

本レポートは、広範な調査を経て作成されました。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行いました。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、定量吸入器市場を把握しました。

本レポートは、世界の定量吸入器市場の競合情勢を掘り下げています。世界の定量吸入器市場で活動する主要企業が特定され、これらの各企業は様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の定量吸入器市場のプレイヤーの属性です。

目次

第1章 序文

  • 市場の定義と範囲
  • 市場セグメンテーション
  • 主な調査目的
  • 調査ハイライト

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：定量吸入器の世界市場

第4章 市場の概要

  • イントロダクション
    • 定義
    • 業界の進化・発展
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 定量吸入器の世界市場の分析と予測、2017-2031年
    • 市場収益予測
  • ポーターのファイブフォース分析

第5章 キーインサイト

  • 呼吸器疾患疫学
  • 技術的な進歩
  • 主なM&A（合併・買収
  • COVID-19パンデミック別産業への影響（バリューチェーンと短期・中期・長期的な影響）。

第6章 定量噴霧式吸入器の世界市場分析・予測：製品タイプ別

  • イントロダクションと定義
  • 主な発見/発展
  • 市場価値予測：製品タイプ別、2017年～2031年
    • 手動式pMDI
    • ブレスアクチュエーターpMDI
  • 市場魅力度分析：製品タイプ別

第7章 定量噴霧式吸入器の世界市場分析・予測：適応疾患別

  • イントロダクションと定義
  • 主な発見/発展
  • 市場価値予測：疾患適応症別、2017-2031年
    • 気管支喘息
    • 慢性閉塞性肺疾患
    • その他
  • 市場魅力度分析：疾患別適応症別

第8章 定量噴霧式吸入器の世界市場分析・予測：流通チャネル別

  • イントロダクションと定義
  • 主な発見/発展
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場魅力度分析：流通チャネル別

第9章 定量噴霧式吸入器の世界市場分析・予測：地域別

  • 主な調査結果
  • 市場価値予測：地域別、2017-2031年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ地域
  • 市場魅力度分析：地域別

第10章 北米の定量噴霧式吸入器の市場分析・予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：製品タイプ別、2017年～2031年
    • 手動式pMDI
    • ブレスアクチュエーターpMDI
  • 市場価値予測：疾患適応症別、2017-2031年
    • 気管支喘息
    • 慢性閉塞性肺疾患
    • その他
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国別、2017年～2031年
    • 米国
    • カナダ
  • 市場の魅力度分析
    • 製品タイプ別
    • 疾患別適応症別
    • 流通チャネル別
    • 国別

第11章 欧州の定量吸入器市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：製品タイプ別、2017年～2031年
    • 手動式pMDI
    • ブレスアクチュエーターpMDI
  • 市場価値予測：疾患適応症別、2017-2031年
    • 気管支喘息
    • 慢性閉塞性肺疾患
    • その他
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国・地域別、2017-2031年
    • ドイツ
    • U.K.
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 市場の魅力度分析
    • 製品タイプ別
    • 疾患別適応症別
    • 流通チャネル別
    • 国・地域別

第12章 アジア太平洋の定量噴霧式吸入器市場の分析・予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：製品タイプ別、2017年～2031年
    • 手動式pMDI
    • ブレスアクチュエーターpMDI
  • 市場価値予測：疾患適応症別、2017-2031年
    • 気管支喘息
    • 慢性閉塞性肺疾患
    • その他
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国・地域別、2017-2031年
    • 中国
    • 日本
    • インド
    • オーストラリア・ニュージーランド
    • その他アジア太平洋地域
  • 市場の魅力度分析
    • 製品タイプ別
    • 疾患別適応症別
    • 流通チャネル別
    • 国・地域別

第13章 ラテンアメリカの定量噴霧式吸入器の市場分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：製品タイプ別、2017年～2031年
    • 手動式pMDI
    • ブレスアクチュエーターpMDI
  • 市場価値予測：疾患適応症別、2017-2031年
    • 気管支喘息
    • 慢性閉塞性肺疾患
    • その他
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国・地域別、2017-2031年
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域
  • 市場の魅力度分析
    • 製品タイプ別
    • 疾患別適応症別
    • 流通チャネル別
    • 国・地域別

第14章 中東・アフリカの定量噴霧式吸入器市場の分析・予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：製品タイプ別、2017年～2031年
    • 手動式pMDI
    • ブレスアクチュエーターpMDI
  • 市場価値予測：疾患適応症別、2017-2031年
    • 気管支喘息
    • 慢性閉塞性肺疾患
    • その他
  • 市場価値予測：流通チャネル別、2017-2031年
    • 病院内薬局
    • 小売薬局
    • オンラインファーマシーズ
  • 市場価値予測：国・地域別、2017-2031年
    • GCC諸国
    • 南ア
    • その他中東・アフリカ地域
  • 市場の魅力度分析
    • 製品タイプ別
    • 疾患別適応症別
    • 流通チャネル別
    • 国・地域別

第15章 競合情勢

  • 市場競争者-競争マトリックス（階層別、企業規模別）
  • 市場シェア分析：企業別（2021年）
  • 企業プロファイル
    • AstraZeneca
    • Cipla Limited
    • Novartis AG
    • Merck & Co., Inc.
    • Sanofi
    • Boehringer Ingelheim
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Hikma Pharmaceuticals plc
    • GlaxoSmithKline
図表

List of Tables

  • Table 01: Global Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 02: Global Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 03: Global Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 07: North America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 08: North America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 11: Europe Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 12: Europe Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 15: Asia Pacific Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 16: Asia Pacific Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 19: Latin America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 20: Latin America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 23: Middle East & Africa Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 24: Middle East & Africa Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Metered Dose Inhalers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Metered Dose Inhalers Market Value Share, by Product Type, 2021
  • Figure 03: Global Metered Dose Inhalers Market Value Share, by Distribution Channel, 2021
  • Figure 04: Global Metered Dose Inhalers Market Value Share, by Disease Indication, 2021
  • Figure 05: Global Metered Dose Inhalers Market Value Share, by Region, 2021
  • Figure 06: Global Metered Dose Inhalers Market Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 07: Global Metered Dose Inhalers Market Value (US$ Mn), by Manual Actuated pMDIs, 2017-2031
  • Figure 08: Global Metered Dose Inhalers Market Value (US$ Mn), by Breath Actuated pMDIs, 2017-2031
  • Figure 09: Global Metered Dose Inhalers Market Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 10: Global Metered Dose Inhalers Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 11: Global Metered Dose Inhalers Market Value (US$ Mn), by Asthma, 2017-2031
  • Figure 12: Global Metered Dose Inhalers Market Value (US$ Mn), by COPD, 2017-2031
  • Figure 13: Global Metered Dose Inhalers Market Value (US$ Mn), by Others, 2017-2031
  • Figure 14: Global Metered Dose Inhalers Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 15: Global Metered Dose Inhalers Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 16: Global Metered Dose Inhalers Market Value (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 17: Global Metered Dose Inhalers Market Value (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 18: Global Metered Dose Inhalers Market Value (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 19: Global Metered Dose Inhalers Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 20: Global Metered Dose Inhalers Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 21: Global Metered Dose Inhalers Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 22: North America Metered Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 23: North America Metered Dose Inhalers Market Value Share (%), by Country, 2021 and 2031
  • Figure 24: North America Metered Dose Inhalers Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 25: North America Metered Dose Inhalers Market Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 26: North America Metered Dose Inhalers Market Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 27: North America Metered Dose Inhalers Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 28: North America Metered Dose Inhalers Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 29: North America Metered Dose Inhalers Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 30: North America Metered Dose Inhalers Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 31: Europe Metered Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 32: Europe Metered Dose Inhalers Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 33: Europe Metered Dose Inhalers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 34: Europe Metered Dose Inhalers Market Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 35: Europe Metered Dose Inhalers Market Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 36: Europe Metered Dose Inhalers Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 37: Europe Metered Dose Inhalers Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 38: Europe Metered Dose Inhalers Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 39: Europe Metered Dose Inhalers Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 40: Asia Pacific Metered Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 41: Asia Pacific Metered Dose Inhalers Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 42: Asia Pacific Metered Dose Inhalers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 43: Asia Pacific Metered Dose Inhalers Market Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 44: Asia Pacific Metered Dose Inhalers Market Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 45: Asia Pacific Metered Dose Inhalers Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 46: Asia Pacific Metered Dose Inhalers Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 47: Asia Pacific Metered Dose Inhalers Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 48: Asia Pacific Metered Dose Inhalers Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 49: Latin America Metered Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 50: Latin America Metered Dose Inhalers Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 51: Latin America Metered Dose Inhalers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 52: Latin America Metered Dose Inhalers Market Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 53: Latin America Metered Dose Inhalers Market Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 54: Latin America Metered Dose Inhalers Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 55: Latin America Metered Dose Inhalers Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 56: Latin America Metered Dose Inhalers Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 57: Latin America Metered Dose Inhalers Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 58: Middle East & Africa Metered Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 59: Middle East & Africa Metered Dose Inhalers Market Value Share (%), by Country/Sub-region, 2021 and 2031
  • Figure 60: Middle East & Africa Metered Dose Inhalers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 61: Middle East & Africa Metered Dose Inhalers Market Value Share Analysis, by Product Type, 2021 and 2031
  • Figure 62: Middle East & Africa Metered Dose Inhalers Market Attractiveness Analysis, by Product Type, 2022-2031
  • Figure 63: Middle East & Africa Metered Dose Inhalers Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 64: Middle East & Africa Metered Dose Inhalers Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 65: Middle East & Africa Metered Dose Inhalers Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 66: Middle East & Africa Metered Dose Inhalers Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 67: Global Metered Dose Inhalers Market Share Analysis, by Company, 2021
目次
Product Code: TMRGL32174

The report provides revenue of the global metered dose inhalers market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global metered dose inhalers market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the metered dose inhalers market.

The report delves into the competitive landscape of the global metered dose inhalers market. Key players operating in the global metered dose inhalers market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global metered dose inhalers market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Metered Dose Inhalers Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Metered Dose Inhalers Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Forces Analysis

5. Key Insights

  • 5.1. Respiratory Disease Epidemiology
  • 5.2. Technological Advancements
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Metered Dose Inhalers Market Analysis and Forecast, by Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2017-2031
    • 6.3.1. Manual Actuated pMDIs
    • 6.3.2. Breath Actuated pMDIs
  • 6.4. Market Attractiveness Analysis, by Product Type

7. Global Metered Dose Inhalers Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 7.3.1. Asthma
    • 7.3.2. COPD
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Disease Indication

8. Global Metered Dose Inhalers Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Metered Dose Inhalers Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Metered Dose Inhalers Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product Type, 2017-2031
    • 10.2.1. Manual Actuated pMDIs
    • 10.2.2. Breath Actuated pMDIs
  • 10.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 10.3.1. Asthma
    • 10.3.2. COPD
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Product Type
    • 10.6.2. By Disease Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Metered Dose Inhalers Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Product Type, 2017-2031
    • 11.2.1. Manual Actuated pMDIs
    • 11.2.2. Breath Actuated pMDIs
  • 11.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 11.3.1. Asthma
    • 11.3.2. COPD
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Product Type
    • 11.6.2. By Disease Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Metered Dose Inhalers Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product Type, 2017-2031
    • 12.2.1. Manual Actuated pMDIs
    • 12.2.2. Breath Actuated pMDIs
  • 12.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 12.3.1. Asthma
    • 12.3.2. COPD
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Product Type
    • 12.6.2. By Disease Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Metered Dose Inhalers Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product Type, 2017-2031
    • 13.2.1. Manual Actuated pMDIs
    • 13.2.2. Breath Actuated pMDIs
  • 13.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 13.3.1. Asthma
    • 13.3.2. COPD
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Product Type
    • 13.6.2. By Disease Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Metered Dose Inhalers Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product Type, 2017-2031
    • 14.2.1. Manual Actuated pMDIs
    • 14.2.2. Breath Actuated pMDIs
  • 14.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 14.3.1. Asthma
    • 14.3.2. COPD
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Product Type
    • 14.6.2. By Disease Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2021)
  • 15.3. Company Profiles
    • 15.3.1. AstraZeneca
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Type Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Cipla Limited
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Type Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Novartis AG
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Type Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Merck & Co., Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Type Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Sanofi
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Type Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
    • 15.3.6. Boehringer Ingelheim
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Type Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
    • 15.3.7. Teva Pharmaceutical Industries Ltd.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Type Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
    • 15.3.8. Mylan N.V.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Type Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
    • 15.3.9. Hikma Pharmaceuticals plc
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Type Portfolio
      • 15.3.9.3. Financial Overview
    • 15.3.10. GlaxoSmithKline
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Type Portfolio
      • 15.3.10.3. Financial Overview